G ene therapy is a promising new treatment mo dality based on molecular genetic modification to achieve a therapeutic benefit. It was originally pro posed as a therapy for genetic or inherited diseases caused by a single gene defect that could be corrected by transfer of a normal copy of the deleted or non functioning gene. As it became clear that changes in gene expression formed the basis of many other diseases, the scope of gene therapy was broadened to include treatment of acute and acquired conditions as well. Over the past decade, this strategy has been applied to a number of diseases affecting most of the organ systems in the body (1) . We will focus here on the potential of gene therapy in the peritoneal cavity, describing strategies by which genetic modification can be used to treat a variety of disease states or conditions.
GENE THERAPY METHODOLOGY
Genetic modification can be defined as the transfer of genetic material into a cell with a subsequent change in gene expression. In most cases, the transferred material consists of an expression cassette containing cDNA sequences for the gene of interest and various regulatory elements -to provide for the production of a protein t o re-establish a biological function or to provide a new one. It is also possible, however, to decrease or to suppress endogenous gene expression (that is, to downregulate the production of a protein that is harmful or required in decreased amounts) through the transfer of antisense oligonucleotides (2) or ribozymes (3), both of which block the expression of targeted mRNAs.
Two main types of delivery systems designed to transfer genetic material into cells have been developed: those involving modified recombinant viruses, and those employing non viral reagents. A number of virus-based gene delivery systems have been described, including those based on recombinant adenoviruses, adeno-associated viruses, and retroviruses (4, 5) . Non viral gene delivery systems encompass a wide range of techniques for introducing genetic information into a cell (6, 7) ; the most commonly used reagent is the cationic liposome.
The genetic modification procedure itself is achieved by one of two strategies, designated ex vivo and in vivo gene therapy. In ex vivo gene therapy, designated cells are removed from the patient, genetically modified in the laboratory, and subsequently reimplanted; whereas in in viva gene therapy, genetic modification is accomplished in situ through the direct delivery of the gene delivery system to the patient.
APPLICATIONS OF GENE THERAPY IN THE PERITONEAL CAVITY
We believe that a variety of conditions in the peritoneal cavity can be addressed by gene therapy. First, we can envision a g ene-therapy strategy involving genetic modification of the peritoneal membrane to improve and enhance its function in peritoneal dialysis (PD). Second, in an approach applicable to but not restricted to PD, the membrane could be modified for local and systemic delivery of therapeutic proteins. Another area that has received significant attention is the treatment of intraabdominal malignancies. Finally, gene transfer could be an extremely valuable tool in understanding the biology of the peritoneal cavity and the peritoneal membrane.
THE MESOTHELIAL CELLAS THE TARGET FOR GENETIC MODIFICATION
To appreciate the potential of changing the characteristics of the peritoneal membrane through genetic modification, one must first have an understanding of the structure and function of this tissue, a subject that has been extensively reviewed (8) (9) (10) . The cells that line the peritoneal cavity, the peritoneal mesothelial cells (MCs), are an ideal target for genetic modification for many reasons. These cells play an active role in maintaining physiological homeostasis. Their anatomical location on the surface of the peritoneal cavity makes them particularly suitable for manipulation. These cells participate in a number of functions, incl uding host defense and response to inflammation, maintenance of the fibrinolytic capacity of the membrane, and membrane repair and remodeling (11) (12) (13) (14) (15) . In addition, MCs are present in large numbers, have a relatively low turnover rate and, as secretory cells, have the capacity to produce factors for systemic as well as local delivery. As such, they are in communication with other cells in the peritoneal membrane (that is, resident and infiltrating leukocytes, peritoneal fibroblasts, and the endothelial cells of the peritoneal microvasculature). Access to the peritoneal cavity for the harvesting of MCs, or for their in situ genetic modification, can be facilitated through placement of an indwelling catheter. These properties make the MC an attractive and manageable target for gene transfer.
Genetic modification of the peritoneal MC for the production of intracellular, cell-surface bound, and secreted proteins has been demonstrated by both ex vivo (16) (17) (18) (19) (20) (21) and in vivo (22) (23) (24) approaches (summarized in Table 1 ). These studies, taken together with previous reports of MC reimplantation in both rabbits and humans (25) , support the concept of a therapy based on genetic modification of the peritoneal mesothelium.
GENE THERAPY FOR PERITONEAL DIALYSIS
Gene therapy for the enhancement ofPD is based on the use of genetically modified MCs to alleviate or to prevent peritoneal membrane injury during PD and to enhance its performance as a dialyzing membrane. PD has been described as a process of chronic injury to the peritoneal membrane, caused in part by continuous exposure to non physiological dialysis solutions and episodes of peritonitis (26) . PD-induced changes in peritoneal membrane structure and function can adversely affect dialyzing capacity and may eventually lead to membrane failure and removal from PD as a treatment modality (8, (27) (28) (29) (30) . Several PD-related pathophysiological conditions may be amenable to improvement through genetic modification of the peritoneal membrane. They include decreased fibrinolytic capacity of the membrane, presence of an inflammatory state, and increased oxidative injury. These conditions, and the corresponding potential therapeutics have been discussed in detail (31) and are summarized in Table 2 .
The current research to evaluate a gene-therapy strategy for P D has taken the form of feasibility studies to demonstrate proof of principle. To prove the benefit of the therapies, we must examine the efficacy of gene therapy for treatment of an existing condition. For example, in a therapy to improve peritoneal membrane viability by increasing the fibrinolytic capacity of the membrane, we must not only demonstrate that the membrane characteristics are changed, but that the change results in a clinical change as well: that is, improved transport and ultrafiltration, and a membrane with fewer adhesions and less fibrin deposition. Interestingly, the use of ex vivo MC-mediated gene therapy for continuous ambulatory peritoneal dialysis (CAPD) was favorably reviewed in a recent commentary (32) .
GENE THERAPY FOR LOCAL AND SYSTEMIC DELIVERY OF THERAPEUTIC PROTEINS
The peritoneal mesothelium may also be well suited for the synthesis and delivery of therapeutic proteins both systemically and to the local environment. Systemic delivery of recombinant human growth hormone ( hGH), erythropoietin (EPO), and &#945;1-antitrypsin from a genetically modified mesothelium has been documented in animal models (18, 19, 23, 24) . These stud ies support the concept of MC-mediated delivery of therapeutic proteins for various pathologies requiring the administration of these or similar proteins and growth factors. One potential application ofMCmediated gene therapy is to provide enzymatic functions normally provided by the kidney (that is, pro duction of EPO), and therefore to be a viable treatment for end-stage renal disease (ESRD) patients. In addition, for patients undergoing abdominal surgery, the transient modification of the peritoneal mesothelium to produce the fibrinolytic factor tissue plasmi nogen activator (tPA) may provide an appropriate level of fibrinolysis to promote tissue repair and prevent post-surgical adhesion formation.
CANCER GENE THERAPY
Another application of gene therapy in the peritoneal cavity focuses on the treatment ofintra-abdomi nal malignancies. The feasibility of gene therapy for cancer has been demonstrated through a number of preclinical and clinical studies, which are the subject of a comprehensive review (33) . One approach is suicide gene therapy involving the transfer of the herpes simplex virus thymidine kinase gene (HSVtk). The HSVtk protein transforms the prodrug ganciclovir into a cytotoxic product, killing not only the HSVtk-expressing cells, but neighboring (non modified) cells as well, a phenomenon known as the bystander effect. Intraperitoneal suicide gene therapy using the HSVtk/ganciclovir combination has been shown to reduce tumor burden in animal models of ovarian cancer (34, 35) , peritoneal mesothelioma (36) , and metastatic pancreatic cancer (37, 38) . A clinical trial based on this approach is in place for the treatment of ovarian and extra ovarian cancer (39) . .
Another approach to treating intra-abdominal carcinomas involves the transfer of tumor suppressor genes, an example of replacement gene therapy. Adenovirus-mediated intraperitoneal delivery of the tumor suppressor protein p53 reduced tumor burden in murine models of bladder cancer (40) and ovarian cancer (41) . Conversely, the same end result might be achieved through inactivation of a functioning oncogene by using antisense technology. Liposomemediated intraperitoneal delivery of antisense oligonucleotides for the K-ras oncogene was effective in a murine model of disseminated pancreatic cancer ( 42) . In these examples of intraperitoneal gene therapy for cancer, both tumor cells and neighboring normal tis sue are genetically modified through intraperitoneal gene delivery. However, because expression of the transferred gene (that is, HSVtk, p53, antisense K-ras) is specifically toxic to cells with abnormal patterns of cell growth (that is, tumor cells), the net resuIt is tumor cell death with little or no effect on normal tissue.
UNDERSTANDING PERITONEAL MEMBRANE BIOLOGY THROUGH GENE TRANSFER
Gene transfer can also be used as a tool to understand peritoneal membrane function and various (patho)physiological processes such as response to infection and inflammation, wound healing, and progression to fibrosis. By being able to manipulate the expression of a specific factor, an understanding can be developed of the role of i ndividual molecules in peritoneal membrane physiology in an in vivo setting. One process that could be examined in this manner is that ofremesothelialization, or regeneration of the MC monolayer after injury or peritonitis. Through marker gene transfer to an intact, denuded, or damaged membrane, one may be able to "tag" the various cell populations found in the mesothelium and submesothelial tissue. In this way, one could follow their participation in re-establishing an intact monolayer, thereby identifying the cells that are involved in tis sue healing and remesothelialization.
One candidate molecule for analysis by gene transfer is transforming growth factor &#946; (TGF&#946;), known to be synthesized by MCs (43) and presumed to be involved in both normal peritoneal wound healing and tissue repair, and in peritoneal fibrosis ( 44) . Gene transfer of the gene for TGF&#946;, or inhibition ofTGF&#946; expression via an antisense strategy, would more clearly define its role in these processes. Indeed, thes e studies could support the development of a therapy to promote normal wound healing and to prevent the progression of events that lead to peritoneal fibrosis and sclerosis.
Finally, this approach can be taken one step further in a knockout mouse model. G ene transfer and subsequent expression of the "knocked out" gene by the peritoneal mesothelium of these animals would allow the physiological role of a particular protein to be defined, as well as the implications of its absence on a specific physiological process in the peritoneal cavity to be analyzed.
REGULATION OF GENE EXPRESSION
We have described several opportunities for therapeutic intervention in the peritoneal cavity using gene-transfer methodologies. However, one issue remains integral to the success of all of these strategies, and that is the control of transgene expression. Whether the therapeutic strategy involves the modification of a normal cellular function (that is, inflammation), or provides for a new one, transgene expression must be tightly controlled to achieve the desired therapeutic end. Control can be provided by pharmacologic and physiological regulatory systems (45, 46) , or through repeated administration of delivery agents designed to give transient expression. The ability to modulate transgene expression from a modified me sothelium (20) and from modified cells implanted in the peritoneal cavity (47) has already been demonstrated. The ultimate challenge for the research investigator and the clinician will be to devise gene therapeutics to provide regulated therapeutic levels of gene expression for a defined period of time, analogous to a drug dosage regimen.
SUMMARY
The use of a gene therapy strategy in the peritoneal cavity to address a variety of conditions and diseases is an exciting and innovative concept. The groundwork to support this approach has been promising. Genetic modification of the peritoneal membrane has been used to change the membrane surface characteristics, to deliver proteins to the systemic circulation, and as the basis for the treatment of in tra-abdominal carcinomas. It is imperative to continue to formulate and test therapeutic platforms to address the diseases and conditions native to the peritoneal cavity. We have the tools to change the genetic makeup of the cell. The challenge we should all accept is to use these tools and creative thinking to make gene therapy in the peritoneal cavity a successful and viable therapeutic approach.
